Factor IX analogues having prolonged in vivo half life

Details for Australian Patent Application No. 2007253264 (hide)

Owner Novo Nordisk Health Care AG

Inventors Stennicke, Henning Ralf; Ostergaard, Henrik; Steenstrup, Thomas Dock; Olsen, Ole Hvilsted

Agent Shelston IP

Pub. Number AU-A-2007253264

PCT Pub. Number WO2007/135182

Priority 06114492.9 24.05.06 EP

Filing date 24 May 2007

Wipo publication date 29 November 2007

International Classifications

C12N 9/64 (2006.01) Enzymes, e.g. ligases (6.) - derived from animal tissue, e.g. rennin

A61K 38/48 (2006.01) Medicinal preparations containing peptides

A61P 7/04 (2006.01) Drugs for disorders of the blood or the extracellular fluid

Event Publications

27 November 2008 PCT application entered the National Phase

  PCT publication WO2007/135182 Priority application(s): WO2007/135182

26 May 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007253269-Catalysis system

2007253255-Corneal implant and method for correction of impaired vision in the human eye